ADMA Biologics to Participate in the Jefferies Virtual Plasma Summit
March 04 2021 - 08:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that Adam Grossman, President and Chief
Executive Officer, will participate in a fireside chat at the
upcoming Jefferies Virtual Plasma Summit being held on Thursday,
March 11, 2021, at 11:20 a.m. ET.
A webcast of the event will be available on the
Company’s website at https://ir.admabiologics.com/events-webcasts
and will be archived for 90 days following the event.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end American
commercial biopharmaceutical company dedicated to manufacturing,
marketing and developing specialty plasma-derived biologics for the
treatment of immunodeficient patients at risk for infection and
others at risk for certain infectious diseases. ADMA currently
manufactures and markets three United States Food and Drug
Administration (FDA) approved plasma-derived biologics for the
treatment of immune deficiencies and the prevention of certain
infectious diseases: BIVIGAM® (immune globulin intravenous, human)
for the treatment of primary humoral immunodeficiency (PI);
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of PI; and NABI-HB® (hepatitis B immune globulin,
human) to provide enhanced immunity against the hepatitis B virus.
ADMA manufactures its immune globulin products at its FDA-licensed
plasma fractionation and purification facility located in Boca
Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also
operates as an FDA-approved source plasma collector in the U.S.,
which provides a portion of its blood plasma for the manufacture of
its products. ADMA’s mission is to manufacture, market and develop
specialty plasma-derived, human immune globulins targeted to niche
patient populations for the treatment and prevention of certain
infectious diseases and management of immune compromised patient
populations who suffer from an underlying immune deficiency, or who
may be immune compromised for other medical reasons. ADMA has
received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793
and 10,259,865 related to certain aspects of its products and
product candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT: Skyler
BloomDirector, Investor Relations and Corporate Strategy |
201-478-5552| sbloom@admabio.com
INVESTOR RELATIONS CONTACT:Sam
MartinManaging Director, Argot Partners | 212-600-1902 |
sam@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2023 to Mar 2024